Streamlining respiratory diagnostics with PCR testing results at the point of patient care

115

Cepheid recently hosted an insightful webinar entitled ‘The importance of diagnosing respiratory symptoms and reliable performance of point-of-care testing.’

This interactive and educational session was presented by international expert speakers, and discussed issues currently being faced by healthcare providers worldwide.

Key topics included the recent emergence of circulating influenza A viruses with genetic drift, and how this increases the risk of false negatives during respiratory testing. The speakers also highlighted the potentially crucial role of fast and accurate RT-PCR-based point-of-care assays, such as the Cepheid Xpert® Xpress respiratory tests, for easing diagnostic bottlenecks and supporting disease control.

If you didn’t catch this fascinating webinar live, you can now watch the recording on-demand through this link.

Click here to Watch Now

Company: Cepheid


Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated molecular diagnostic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

Send Enquiry for this story

By submitting this form you are giving a consent to HHMGlobal.com to store your submitted information.
See our Privacy Policy to learn more about how we use data.